Document Detail


Bicyclol: a novel drug for treating chronic viral hepatitis B and C.
MedLine Citation:
PMID:  19149648     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic viral hepatitis B and C are diseases worldwide. At present, the number of effective and safe drugs for treatment of HBV and HCV is still limited. In order to develop novel anti-viral hepatitis drug, a number of analogues of the active component schizandrin C from Fructus Schiznadrae, a Chinese herb used in the therapy of viral hepatitis, were synthesized. Bicyclol, one of the analogues, was demonstrated to have actions of anti-hepatitis virus replication in duck hepatitis model and 2.2.15 cell line, anti-experimental liver injury induced by hepatotoxins such as CCl4, acetaminophen and ConA, and anti-liver fibrosis in rats and mice. The active mechanism of bicyclol might be anti-apoptosis of hepatocytes through multiple signaling pathways mainly inducing the expressions of hepatic heat shock proteins (HSP27 and HSP70), molecular chaperons. Clinical trial was performed by double blind, randomized and positive control or placebo method in multi-medical centers in China. Patients received bicyclol 25mg thrice daily for six months, then stopped treatment and followed up for 3 months. Oral administration of bicyclol normalized the elevated serum transaminases (ALT, AST) by approximately 50% in chronic viral hepatitis B and C, and also showed certain level of inhibiting HBV and HCV replication. No noticeable adverse reaction has been observed. In combination therapy of bicyclol with interferon alpha, lamivudine and adefovir dipivoxil in HBV or HCV, bicyclol may potentiate the anti-viral efficacy and reduce YMDD mutant and side effects. In 2004 China FDA issued license to manufacture bicyclol. Since then bicyclol has been widely used to treat chronic HBV and HCV in China.
Authors:
Geng Tao Liu
Related Documents :
16565668 - Fatal hepatic decompensation in a bone marrow transplant recipient with hbv-related cir...
12085368 - Course of virologic breakthroughs under long-term lamivudine in hbeag-negative precore ...
17682998 - Hepatitis b virus and hiv coinfection: results of a survey on treatment practices and r...
15196068 - Prospective study on lamivudine-resistant hepatitis b in renal allograft recipients.
18040818 - Hiv preclinical-clinical therapeutics research: central nervous system approaches.
87618 - Non-a non-b hepatitis associated with chronic liver disease in a haemodialysis unit.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Medicinal chemistry (Shāriqah (United Arab Emirates))     Volume:  5     ISSN:  1573-4064     ISO Abbreviation:  -     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2009-01-19     Completed Date:  2009-03-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101240303     Medline TA:  Med Chem     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  29-43     Citation Subset:  IM    
Affiliation:
Department of Pharmacology, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China. liugt@imm.ac.cn
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antiviral Agents / chemistry,  therapeutic use*
Biphenyl Compounds / chemistry,  therapeutic use*
Hepatitis B, Chronic / drug therapy*
Hepatitis C, Chronic / drug therapy*
Humans
Molecular Structure
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Biphenyl Compounds; 0/bicyclol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A model on the induction of adverse vascular long-term effects of NSAIDs.
Next Document:  Effects of magnetic stimulation on oxidative stress and skeletal muscle regeneration induced by mepi...